Creative Medical Technology shares shareholder letter on clinical progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/20/2026
- Nasdaq futures fall as oil prices jump, key earnings loom
- Brent hits five-month high as attacks on ships, Saudi sites fuel supply worries
- Loop Capital downgrades Apple, sees no recovery of cut iPhone shipments
- Wells Fargo says S&P 500 buy signal emerges as investors turn excessively bearish
- ByteDance, Alibaba and Tencent order $35 billion of Nvidia chips: Reuters
Creative Medical Technology Holdings Issues Letter to Shareholders
October 27, 2025 8:15 AM EDTPHOENIX, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (Creative Medical or the Company), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today issued a Letter to Shareholders from Timothy Warbington, Co-Founder and Chief Executive Officer.
Dear Fellow Shareholders:
2025 has been a landmark year for Creative Medical. With the support of the most comprehensive clinical, intellectual, and technological foundation in our Companys history, we have evolved from proof-of-concept to clinical trials in support of our mission to develop breakthrough regenerative... More



